FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:994-1004 March 13, 2003 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Peggs, K. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML.

Methods We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates of progression.

Results After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy.

Conclusions In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.

Source Information

From the University of Newcastle, Newcastle, United Kingdom (S.G.O.); Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); University of Chicago, Chicago (R.A.L.); Novartis, Basel, Switzerland (I.G., A.E.B., R.C.); Policlinico S. Orsola–Malpighi, Bologna, Italy (M.B.); Hospital Clinic I Provincial, Barcelona, Spain (F.C.); Erasmus Medical Center, Daniel Den Hoed Cancer Center, Rotterdam, the Netherlands (J.J.C.); Johannes-Gutenberg-Universität, Mainz, Germany (T.F.); Klinikum Mannheim, Universität Heidelberg, Mannheim, Germany (A.H.); Royal Adelaide Hospital, Adelaide, Australia (T.H.); Universitäts Klinik für Innere Medizin I, Vienna, Austria (K.L.); Aarhus Amtssygehus, Aarhus, Denmark (J.L.N.); Hôpital Saint Louis, Paris (P.R.); Centre Hospitalier Universitaire de Bordeaux, Pessac, France (J.R.); Azienda Ospedaliera S. Luigi Gonzaga, Orbassano, Italy (G.S.); Vancouver Hospital, Vancouver, Canada (J.S.); Akademiska Sjukhuset, Uppsala, Sweden (B.S.); Kantonsspital Basel, Switzerland (A.G.); Hammersmith Hospital, London (J.M.G.); M.D. Anderson Cancer Center, Houston (H.K.); Mater Misericordiae Public Hospital, Brisbane, Australia (K.T.); University Hospital Gasthuisberg, Leuven, Belgium (G.V.); and Oregon Health and Science University Cancer Institute, Portland (B.J.D.).

Full Text of this Article

This article has been cited by other articles:

• Chapuy, B., Panse, M., Radunski, U., Koch, R., Wenzel, D., Inagaki, N., Haase, D., Truemper, L., Wulf, G. G. (2009). ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. haematol 94: 1528-1536 [Abstract] [Full Text]  
• Radich, J. P. (2009). How I monitor residual disease in chronic myeloid leukemia. Blood 114: 3376-3381 [Abstract] [Full Text]  
• Cortes, J. E., Kantarjian, H. M., Goldberg, S. L., Powell, B. L., Giles, F. J., Wetzler, M., Akard, L., Burke, J. M., Kerr, R., Saleh, M., Salvado, A., McDougall, K., Albitar, M., Radich, J. (2009). High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses. JCO 27: 4754-4759 [Abstract] [Full Text]  
• Press, R. D., Willis, S. G., Laudadio, J., Mauro, M. J., Deininger, M. W. N. (2009). Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 114: 2598-2605 [Abstract] [Full Text]  
• Verma, D., Kantarjian, H. M., Jones, D., Luthra, R., Borthakur, G., Verstovsek, S., Rios, M. B., Cortes, J. (2009). Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 114: 2232-2235 [Abstract] [Full Text]  
• Jabbour, E., Jones, D., Kantarjian, H. M., O'Brien, S., Tam, C., Koller, C., Burger, J. A., Borthakur, G., Wierda, W. G., Cortes, J. (2009). Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114: 2037-2043 [Abstract] [Full Text]  
• Kantarjian, H. M., Shan, J., Jones, D., O'Brien, S., Rios, M. B., Jabbour, E., Cortes, J. (2009). Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. JCO 27: 3659-3663 [Abstract] [Full Text]  
• Grosso, S., Puissant, A., Dufies, M., Colosetti, P., Jacquel, A., Lebrigand, K., Barbry, P., Deckert, M., Cassuto, J. P., Mari, B., Auberger, P. (2009). Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Molecular Cancer Therapeutics 8: 1924-1933 [Abstract] [Full Text]  
• Quintas-Cardama, A., Kantarjian, H., Jones, D., Shan, J., Borthakur, G., Thomas, D., Kornblau, S., O'Brien, S., Cortes, J. (2009). Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113: 6315-6321 [Abstract] [Full Text]  
• Mishra, S., Bhatnagar, S., Gupta, D., Gaurav Nirvani Goyal, , Agrawal, R., Jain, R., Chauhan, H. (2009). Respiratory Support in Oncology Ward Setting: A Prospective Descriptive Study. AM J HOSP PALLIAT CARE 26: 159-164 [Abstract]  
• Eley, T., Luo, F. R., Agrawal, S., Sanil, A., Manning, J., Li, T., Blackwood-Chirchir, A., Bertz, R. (2009). Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects. J Clin Pharmacol 49: 700-709 [Abstract] [Full Text]  
• Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachee, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., De Geest, S., Albrecht, T., Abraham, I. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113: 5401-5411 [Abstract] [Full Text]  
• Baccarani, M., Rosti, G., Castagnetti, F., Haznedaroglu, I., Porkka, K., Abruzzese, E., Alimena, G., Ehrencrona, H., Hjorth-Hansen, H., Kairisto, V., Levato, L., Martinelli, G., Nagler, A., Lanng Nielsen, J., Ozbek, U., Palandri, F., Palmieri, F., Pane, F., Rege-Cambrin, G., Russo, D., Specchia, G., Testoni, N., Weiss-Bjerrum, O., Saglio, G., Simonsson, B. (2009). Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113: 4497-4504 [Abstract] [Full Text]  
• Tyler, T. (2009). Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia. The Annals of Pharmacotherapy 43: 920-927 [Abstract] [Full Text]  
• Castagnetti, F., Palandri, F., Amabile, M., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Breccia, M., Rege Cambrin, G., Stagno, F., Specchia, G., Galieni, P., Iuliano, F., Pane, F., Saglio, G., Alimena, G., Martinelli, G., Baccarani, M., Rosti, G., for the GIMEMA CML Working Party, (2009). Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 113: 3428-3434 [Abstract] [Full Text]  
• O'Sullivan, S., Horne, A., Wattie, D., Porteous, F., Callon, K., Gamble, G., Ebeling, P., Browett, P., Grey, A. (2009). Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib. J. Clin. Endocrinol. Metab. 94: 1131-1136 [Abstract] [Full Text]  
• Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]  
• Lagas, J. S., van Waterschoot, R. A.B., van Tilburg, V. A.C.J., Hillebrand, M. J., Lankheet, N., Rosing, H., Beijnen, J. H., Schinkel, A. H. (2009). Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment. Clin. Cancer Res. 15: 2344-2351 [Abstract] [Full Text]  
• Gobbi, G., Mirandola, P., Carubbi, C., Micheloni, C., Malinverno, C., Lunghi, P., Bonati, A., Vitale, M. (2009). Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. Blood 113: 3080-3087 [Abstract] [Full Text]  
• Jabbour, E., Kantarjian, H. M., Jones, D., Shan, J., O'Brien, S., Reddy, N., Wierda, W. G., Faderl, S., Garcia-Manero, G., Verstovsek, S., Rios, M. B., Cortes, J. (2009). Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113: 2154-2160 [Abstract] [Full Text]  
• Daniels, J. M. A., Vonk-Noordegraaf, A., Janssen, J. J. W. M., Postmus, P. E., van Altena, R. (2009). Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 33: 670-672 [Abstract] [Full Text]  
• Wong, S.-F. (2009). Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia. J Oncol Pharm Pract 15: 17-27 [Abstract]  
• Bach, P. B. (2009). Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. NEJM 360: 626-633 [Full Text]  
• Palandri, F., Iacobucci, I., Soverini, S., Castagnetti, F., Poerio, A., Testoni, N., Alimena, G., Breccia, M., Rege-Cambrin, G., Tiribelli, M., Varaldo, R., Abruzzese, E., Martino, B., Luciano, L., Pane, F., Saglio, G., Martinelli, G., Baccarani, M., Rosti, G. (2009). Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. Clin. Cancer Res. 15: 1059-1063 [Abstract] [Full Text]  
• Hayat, A., McCann, S. R., Langabeer, S., Irvine, S., McMullin, M. F., Conneally, E. (2009). Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. haematol 94: 296-298 [Full Text]  
• Jabbour, E., Cortes, J. E., Kantarjian, H. M. (2009). Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?. Mayo Clin Proc. 84: 161-169 [Abstract] [Full Text]  
• Yong, A. S. M., Keyvanfar, K., Hensel, N., Eniafe, R., Savani, B. N., Berg, M., Lundqvist, A., Adams, S., Sloand, E. M., Goldman, J. M., Childs, R., Barrett, A. J. (2009). Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113: 875-882 [Abstract] [Full Text]  
• Bixby, D., Talpaz, M. (2009). Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia. Am Soc Clin Oncol Ed Book 2009: 395-401 [Abstract] [Full Text]  
• Peppercorn, J., Burstein, H., Miller, F. G., Winer, E., Joffe, S. (2008). Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy. JCO 26: 5994-6000 [Abstract] [Full Text]  
• Druker, B. J. (2008). Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817 [Abstract] [Full Text]  
• Agirre, X., Jimenez-Velasco, A., San Jose-Eneriz, E., Garate, L., Bandres, E., Cordeu, L., Aparicio, O., Saez, B., Navarro, G., Vilas-Zornoza, A., Perez-Roger, I., Garcia-Foncillas, J., Torres, A., Heiniger, A., Calasanz, M. J., Fortes, P., Roman-Gomez, J., Prosper, F. (2008). Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. Mol Cancer Res 6: 1830-1840 [Abstract] [Full Text]  
• Liapis, K., Apostolidis, J., Charitaki, E., Panitsas, F., Harhalakis, N., Nikiforakis, E. (2008). Syndrome of Inappropriate Secretion of Antidiuretic Hormone Associated with Imatinib. The Annals of Pharmacotherapy 42: 1882-1886 [Abstract] [Full Text]  
• Kolb, H.-J. (2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112: 4371-4383 [Abstract] [Full Text]  
• Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M. F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A. K., Fay, K., Durrant, S., Januszewicz, H., Joske, D., Underhill, C., Dunkley, S., Lynch, K., Grigg, A., on behalf of the Australasian Leukaemia and Lympho, (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112: 3965-3973 [Abstract] [Full Text]  
• Zhou, L. L., Zhao, Y., Ringrose, A., DeGeer, D., Kennah, E., Lin, A. E.-J., Sheng, G., Li, X.-J., Turhan, A., Jiang, X. (2008). AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. JEM 205: 2657-2671 [Abstract] [Full Text]  
• Lee, S. J., Kukreja, M., Wang, T., Giralt, S. A., Szer, J., Arora, M., Woolfrey, A. E., Cervantes, F., Champlin, R. E., Gale, R. P., Halter, J., Keating, A., Marks, D. I., McCarthy, P. L., Olavarria, E., Stadtmauer, E. A., Abecasis, M., Gupta, V., Khoury, H. J., George, B., Hale, G. A., Liesveld, J. L., Rizzieri, D. A., Antin, J. H., Bolwell, B. J., Carabasi, M. H., Copelan, E., Ilhan, O., Litzow, M. R., Schouten, H. C., Zander, A. R., Horowitz, M. M., Maziarz, R. T. (2008). Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112: 3500-3507 [Abstract] [Full Text]  
• Khorashad, J. S., de Lavallade, H., Apperley, J. F., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., Marin, D. (2008). Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression. JCO 26: 4806-4813 [Abstract] [Full Text]  
• Giles, I, Lambrianides, A, Rahman, A (2008). Examining the non-linear relationship between monoclonal antiphospholipid antibody sequence, structure and function. Lupus 17: 895-903 [Abstract]  
• Okabe, S., Tauchi, T., Ohyashiki, K. (2008). Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells. Clin. Cancer Res. 14: 6181-6186 [Abstract] [Full Text]  
• Lecuyer, L., Chevret, S., Guidet, B., Aegerter, P., Martel, P., Schlemmer, B., Azoulay, E. (2008). Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J 32: 748-754 [Abstract] [Full Text]  
• Ross, D. M., Watkins, D. B., Hughes, T. P., Branford, S. (2008). Reverse Transcription with Random Pentadecamer Primers Improves the Detection Limit of a Quantitative PCR Assay for BCR-ABL Transcripts in Chronic Myeloid Leukemia: Implications for Defining Sensitivity in Minimal Residual Disease. Clin. Chem. 54: 1568-1571 [Abstract] [Full Text]  
• Mohty, M., Szydlo, R. M., Yong, A. S. M., Apperley, J. F., Goldman, J. M., Melo, J. V. (2008). Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. Blood 112: 2163-2166 [Abstract] [Full Text]  
• de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., Marin, D. (2008). Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. JCO 26: 3358-3363 [Abstract] [Full Text]  
• Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., Dobrzanski, P. (2008). Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671 [Abstract] [Full Text]  
• Puissant, A., Grosso, S., Jacquel, A., Belhacene, N., Colosetti, P., Cassuto, J.-P., Auberger, P. (2008). Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J. 22: 1894-1904 [Abstract] [Full Text]  
• Heaney, N. B., Copland, M., Stewart, K., Godden, J., Parker, A. N., McQuaker, I. G., Smith, G. M., Crawley, C., Shepherd, P., Holyoake, T. L. (2008). Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood 111: 5252-5255 [Abstract] [Full Text]  
• Muller, M., Obeyesekere, M., Mills, G. B., Ram, P. T. (2008). Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J. 22: 1393-1403 [Abstract] [Full Text]  
• Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S. G., Seymour, J., Di Scala, L., van Oosterom, A., Herrmann, R., Nikolova, Z., McArthur, a. G., for the Imatinib Target Exploration Consortium Stu, (2008). Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases. Clin. Cancer Res. 14: 2717-2725 [Abstract] [Full Text]  
• La Rosee, P., Holm-Eriksen, S., Konig, H., Hartel, N., Ernst, T., Debatin, J., Mueller, M. C., Erben, P., Binckebanck, A., Wunderle, L., Shou, Y., Dugan, M., Hehlmann, R., Ottmann, O. G., Hochhaus, A. (2008). Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. haematol 93: 765-769 [Abstract] [Full Text]  
• Palandri, F., Iacobucci, I., Castagnetti, F., Testoni, N., Poerio, A., Amabile, M., Breccia, M., Intermesoli, T., Iuliano, F., Rege-Cambrin, G., Tiribelli, M., Miglino, M., Pane, F., Saglio, G., Martinelli, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA Working Party on CML, (2008). Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome. haematol 93: 770-774 [Abstract] [Full Text]  
• Jimeno, A., Tan, A. C., Coffa, J., Rajeshkumar, N.V., Kulesza, P., Rubio-Viqueira, B., Wheelhouse, J., Diosdado, B., Messersmith, W. A., Iacobuzio-Donahue, C., Maitra, A., Varella-Garcia, M., Hirsch, F. R., Meijer, G. A., Hidalgo, M. (2008). Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. Cancer Res. 68: 2841-2849 [Abstract] [Full Text]  
• Larson, R. A., Druker, B. J., Guilhot, F., O'Brien, S. G., Riviere, G. J., Krahnke, T., Gathmann, I., Wang, Y., for the IRIS (International Randomized Interferon, (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111: 4022-4028 [Abstract] [Full Text]  
• Gontarewicz, A., Balabanov, S., Keller, G., Colombo, R., Graziano, A., Pesenti, E., Benten, D., Bokemeyer, C., Fiedler, W., Moll, J., Brummendorf, T. H. (2008). Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111: 4355-4364 [Abstract] [Full Text]  
• Ramirez, P., DiPersio, J. F. (2008). Therapy Options in Imatinib Failures. The Oncologist 13: 424-434 [Abstract] [Full Text]  
• Carayol, N., Katsoulidis, E., Sassano, A., Altman, J. K., Druker, B. J., Platanias, L. C. (2008). Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway. J. Biol. Chem. 283: 8601-8610 [Abstract] [Full Text]  
• Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R., Holyoake, T. L. (2008). BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111: 2843-2853 [Abstract] [Full Text]  
• Deenik, W., van der Holt, B., Verhoef, G. E. G., Smit, W. M., Kersten, M. J., Kluin-Nelemans, H. C., Verdonck, L. F., Ferrant, A., Schattenberg, A. V. M. B., Janssen, J. J. W. M., Sonneveld, P., van Marwijk Kooy, M., Wittebol, S., Willemze, R., Wijermans, P. W., Westveer, P. H. M., Beverloo, H. B., Valk, P., Lowenberg, B., Ossenkoppele, G. J., Cornelissen, J. J. (2008). Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 111: 2581-2588 [Abstract] [Full Text]  
• Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K., Nakamura, H., Derdak, S., Samorapoompichit, P., Pickl, W. F., Sexl, V., Esterbauer, H., Schwarzinger, I., Sillaber, C., Maeda, H., Valent, P. (2008). Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111: 2200-2210 [Abstract] [Full Text]  
• le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., Kuliczkowski, K., Hochhaus, A., Mahon, F.-X., Saglio, G., Gobbi, M., Kwong, Y.-L., Baccarani, M., Hughes, T., Martinelli, G., Radich, J. P., Zheng, M., Shou, Y., Kantarjian, H. (2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111: 1834-1839 [Abstract] [Full Text]  
• Kantarjian, H., Schiffer, C., Jones, D., Cortes, J. (2008). Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111: 1774-1780 [Full Text]  
• Baccarani, M., Pane, F., Saglio, G. (2008). Monitoring treatment of chronic myeloid leukemia. haematol 93: 161-169 [Full Text]  
• Huguet, F., Giocanti, N., Hennequin, C., Croisy, M., Touboul, E., Favaudon, V. (2008). Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells. Molecular Cancer Therapeutics 7: 398-406 [Abstract] [Full Text]  
• Lundan, T., Juvonen, V., Mueller, M. C., Mustjoki, S., Lakkala, T., Kairisto, V., Hochhaus, A., Knuutila, S., Porkka, K. (2008). Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. haematol 93: 178-185 [Abstract] [Full Text]  
• Marshall, H. M, Hammond, J. M (2008). Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia. The Annals of Pharmacotherapy 42: 259-264 [Abstract] [Full Text]  
• Duncan, E. A., Goetz, C. A., Stein, S. J., Mayo, K. J., Skaggs, B. J., Ziegelbauer, K., Sawyers, C. L., Baldwin, A. S. (2008). I{kappa}B kinase {beta} inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular Cancer Therapeutics 7: 391-397 [Abstract] [Full Text]  
• Mesa, R. A. (2008). Not too late for imatinib. Blood 111: 973-974 [Full Text]  
• Hochhaus, A., Druker, B., Sawyers, C., Guilhot, F., Schiffer, C. A., Cortes, J., Niederwieser, D. W., Gambacorti-Passerini, C., Stone, R. M., Goldman, J., Fischer, T., O'Brien, S. G., Reiffers, J. J., Mone, M., Krahnke, T., Talpaz, M., Kantarjian, H. M. (2008). Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment. Blood 111: 1039-1043 [Abstract] [Full Text]  
• Brave, M., Goodman, V., Kaminskas, E., Farrell, A., Timmer, W., Pope, S., Harapanhalli, R., Saber, H., Morse, D., Bullock, J., Men, A., Noory, C., Ramchandani, R., Kenna, L., Booth, B., Gobburu, J., Jiang, X., Sridhara, R., Justice, R., Pazdur, R. (2008). Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate. Clin. Cancer Res. 14: 352-359 [Abstract] [Full Text]  
• Woolf, S. H. (2008). The Meaning of Translational Research and Why It Matters. JAMA 299: 211-213 [Full Text]  
• Saglio, G., Pane, F., Martinelli, G. (2008). State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia. Am Soc Clin Oncol Ed Book 2008: 313-317 [Abstract] [Full Text]  
• Frame, D. (2007). Introduction. Am J Health Syst Pharm 64: S2-S3 [Full Text]  
• Sessions, J. (2007). Chronic myeloid leukemia in 2007. Am J Health Syst Pharm 64: S4-S9 [Abstract] [Full Text]  
• Fausel, C. (2007). Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm 64: S9-S15 [Abstract] [Full Text]  
• Schnipper, L. E. (2007). Update in Oncology. ANN INTERN MED 147: 775-782 [Full Text]  
• Gratwohl, A., Baldomero, H., Schwendener, A., Gratwohl, M., Apperley, J., Niederwieser, D., Frauendorfer, K., for the Joint Accreditation Committee of the Inter, (2007). Predictability of hematopoietic stem cell transplantation rates. haematol 92: 1679-1686 [Abstract] [Full Text]  
• Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., Hughes, T. (2007). BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria. Clin. Cancer Res. 13: 7080-7085 [Abstract] [Full Text]  
• Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., Bhatia, R., Cervantes, F., Haque, A., Shou, Y., Resta, D. J., Weitzman, A., Hochhaus, A., le Coutre, P. (2007). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546 [Abstract] [Full Text]  
• Agis, H., Sperr, W. R., Herndlhofer, S., Semper, H., Pirc-Danoewinata, H., Haas, O. A., Mannhalter, C., Esterbauer, H., Geissler, K., Sillaber, C., Jager, U., Valent, P. (2007). Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 18: 1834-1841 [Abstract] [Full Text]  
• Jabbour, E., Kantarjian, H. M., Abruzzo, L. V., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Shan, J., Rios, M. B., Cortes, J. (2007). Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110: 2991-2995 [Abstract] [Full Text]  
• Goldman, J. M. (2007). How I treat chronic myeloid leukemia in the imatinib era. Blood 110: 2828-2837 [Abstract] [Full Text]  
• Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., Gollerkeri, A., Coutre, S. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309-2315 [Abstract] [Full Text]  
• Baccarani, M., Cilloni, D., Rondoni, M., Ottaviani, E., Messa, F., Merante, S., Tiribelli, M., Buccisano, F., Testoni, N., Gottardi, E., de Vivo, A., Giugliano, E., Iacobucci, I., Paolini, S., Soverini, S., Rosti, G., Rancati, F., Astolfi, C., Pane, F., Saglio, G., Martinelli, G. (2007). The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR{alpha}-positive hypereosinophilic syndrome. Results of a multicenter prospective study. haematol 92: 1173-1179 [Abstract] [Full Text]  
• Nicolini, F. E., Hayette, S., Corm, S., Bachy, E., Bories, D., Tulliez, M., Guilhot, F., Legros, L., Maloisel, F., Kiladjian, J.-J., Mahon, F.-X., Le, Q.-H., Michallet, M., Roche-Lestienne, C., Preudhomme, C. (2007). Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. haematol 92: 1238-1241 [Abstract] [Full Text]  
• Schiffer, C. A. (2007). BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. NEJM 357: 258-265 [Full Text]  
• Chu, S., Li, L., Singh, H., Bhatia, R. (2007). BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia. Cancer Res. 67: 7045-7053 [Abstract] [Full Text]  
• Boddy, A. V., Sludden, J., Griffin, M. J., Garner, C., Kendrick, J., Mistry, P., Dutreix, C., Newell, D. R., O'Brien, S. G. (2007). Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia. Clin. Cancer Res. 13: 4164-4169 [Abstract] [Full Text]  
• Yong, A. S. M., Rezvani, K., Savani, B. N., Eniafe, R., Mielke, S., Goldman, J. M., Barrett, A. J. (2007). High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 110: 770-775 [Abstract] [Full Text]  
• Rink, L., Slupianek, A., Stoklosa, T., Nieborowska-Skorska, M., Urbanska, K., Seferynska, I., Reiss, K., Skorski, T. (2007). Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood 110: 651-660 [Abstract] [Full Text]  
• Mohty, M., Yong, A. S. M., Szydlo, R. M., Apperley, J. F., Melo, J. V. (2007). The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110: 380-383 [Abstract] [Full Text]  
• Yan, M., Luo, J.-K., Ritchie, K. J., Sakai, I., Takeuchi, K., Ren, R., Zhang, D.-E. (2007). Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood 110: 305-312 [Abstract] [Full Text]  
• Modi, H., McDonald, T., Chu, S., Yee, J.-K., Forman, S. J., Bhatia, R. (2007). Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 109: 5411-5421 [Abstract] [Full Text]  
• Volpe, G., Cignetti, A., Panuzzo, C., Kuka, M., Vitaggio, K., Brancaccio, M., Perrone, G., Rinaldi, M., Prato, G., Fava, M., Geuna, M., Pautasso, M., Casnici, C., Signori, E., Tonon, G., Tarone, G., Marelli, O., Fazio, V. M., Saglio, G. (2007). Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches. Cancer Res. 67: 5300-5307 [Abstract] [Full Text]  
• Ray, A., Cowan-Jacob, S. W., Manley, P. W., Mestan, J., Griffin, J. D. (2007). Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109: 5011-5015 [Abstract] [Full Text]  
• Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A., Hasford, J., Kolb, H.-J., Lahaye, T., Maywald, O., Reiter, A., Hossfeld, D. K., Huber, C., Loffler, H., Pralle, H., Queisser, W., Tobler, A., Nerl, C., Solenthaler, M., Goebeler, M. E., Griesshammer, M., Fischer, T., Kremers, S., Eimermacher, H., Pfreundschuh, M., Hirschmann, W.-D., Lechner, K., Wassmann, B., Falge, C., Kirchner, H. H., Gratwohl, A., for the Schweizerische Arbeitsgemeinschaft fur Kli, (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109: 4686-4692 [Abstract] [Full Text]  
• Jiang, X., Saw, K. M., Eaves, A., Eaves, C. (2007). Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells. JNCI J Natl Cancer Inst 99: 680-693 [Abstract] [Full Text]  
• Hoover, A. C., Spanos, W. C., Harris, G. F., Anderson, M. E., Klingelhutz, A. J., Lee, J. H. (2007). The Role of Human Papillomavirus 16 E6 in Anchorage-Independent and Invasive Growth of Mouse Tonsil Epithelium. Arch Otolaryngol Head Neck Surg 133: 495-502 [Abstract] [Full Text]